{"nct_id":"NCT05687266","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-06","start_date":"2022-12-29","start_date_type":"ACTUAL","primary_completion_date":"2027-11-01","primary_completion_date_type":"ESTIMATED","completion_date":"2027-11-01","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}